Study Endpoints 3.4.1. Primary Endpoint s The primary efficacy endpoint is the change in number of mesothelin- specific T cells producing interferon gamma ( IFN-γ) by ELISPOT ( enzyme- linked immunosorbent spot) assay from baseline to: • immediately after CRS- 207 (with or without Cy); • after receiving chemotherapy; • and after receiving two subsequent doses of CRS -207 (with or without Cy) following chemotherapy. Safety will be assessed by evaluation of the fol lowing : • Adverse events (AEs) • Deaths • Vital signs • Physical examination findings • Clinical chemistry and hematology laboratory findings 3.4.2. Secondary Endpoints The following secondary endpoints will be used to assess efficacy: • Objective tumor response • Progression free survival (PFS) • Time to progression (TTP) • Overall survival (OS) • Measure of serum mesothelin to assess predictive value for therapeutic response Tumor response and progression will be assessed using modified Response Evaluation Criteria in Solid Tumors (mRECIST )3 for assessment of response in MPM and irRC4. This ASAP will not include the analysis of primary or secondary efficacy endpoints. Tumor and overall response data, based on mRECIST only, will be listed (irRC based Aduro Biotech, Inc. CONFIDENTIAL Protocol ADU -CL-02 Final Version 1 Page 11 of 24 04MAY2018 outcomes will not be provided); the handling of the primary endpoint will be as described in Section 2 and Section 3.4.3. 3.4.3. Exploratory Endpoints The exploratory endpoints described in this analysis plan are: • Pulmonary function tests (PFTs) measured by forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1) and vital capacity (VC) [for Cohort 2 only] Additional endpoints, corresponding to exploratory objectives, will be evaluated based on a separate, standalone document . This ASAP will not include the analysis of the exploratory endpoints. PFTs will be listed as described in Sectio n 5.11.2. The analysis of the other exploratory objectives will be discussed in another standalone document . Aduro Biotech, Inc. CONFIDENTIAL Protocol ADU -CL-02 Final Version 1 Page 12 of 24 04MAY2018 4. SUBJECT POPULATIONS 4.1. Population Definitions The following subject populations will be evaluated and used for presentation and analysis of the data: • Full Analysis Set (FAS): A ll enrolled subjects who received at least one dose of study treatment . The FAS will be used for all analys es of efficacy and safety . The final SAP version 1.0 used FAS as the analysis dataset. This definition is the same as the definition of the Safety Analysis Set. The FAS now is replaced by the Safety Analysis Set. 4.2.